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This study aimed to evaluate tumour hypoxia by comparing [
18F]Fluoromisonidazole uptake measured using positron emission
tomography ([
18F]FMISO-PET) with immunohistochemical (IHC) staining techniques. Syngeneic rhabdomyosarcoma (R1) tumour
pieces were transplanted subcutaneously in the flanks of WAG/Rij rats. Tumours were analysed at volumes between 0.9 and 7.3cm
3.
Hypoxic volumes were defined using a 3D region of interest on 2h postinjection [
18F]FMISO-PET images, applying different
thresholds (1.2–3.0). Monoclonal antibodies to pimonidazole (PIMO) and carbonic anhydrase IX (CA IX), exogenous and
endogenous markers of hypoxia, respectively, were used for IHC staining. Marker-positive fractions were microscopically measured
for each tumour, and hypoxic volumes were calculated. A heterogeneous distribution of hypoxia was observed both with histology
and [
18F]FMISO autoradiography. A statistically significant correlation (Po0.05) was obtained between the hypoxic volumes defined
with [
18F]FMISO-PET and the volumes derived from the PIMO-stained tumour sections (r¼0.9066; P¼0.0001), regardless of the
selected threshold between 1.4 and 2.2. A similar observation was made with the CA IX staining (r¼0.8636; P¼0.0006). The
relationship found between [
18F]FMISO-PET and PIMO- and additionally CA IX-derived hypoxic volumes in rat rhabdomyosarcomas
indicates the value of the noninvasive imaging method to measure hypoxia in whole tumours.
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As a result of rapid growth and insufficient blood supply, solid
tumours demonstrate hypoxia and necrosis in heterogeneous
spread regions (Chapman, 1984; Vaupel et al, 1989). The presence
of hypoxia is a major cause of resistance to cancer treatment.
Hypoxia has been shown to be an independent predictor of poor
progression-free survival in several types of cancer (Brizel et al,
1997; Nordsmark and Overgaard, 2000; Fyles et al, 2002; Kaanders
et al, 2002). Treatments to overcome the effect from a hypoxic
environment are being evaluated (Brown, 1999; Wouters et al,
2003). Therefore, the assessment of tumour oxygenation will be
valuable to guide treatment in individual patients.
To date, various methods are available to measure tumour
oxygenation, including polarographic oxygen sensors (Vaupel et al,
1991), luminescence-based optical sensors (Bussink et al, 2000)
and antibody-based detection of exogenous (Haustermans et al,
2000; Raleigh et al, 2001; Koch, 2002) and endogenous markers of
hypoxia (Wykoff et al, 2000; Janssen et al, 2002; Airley et al, 2003).
At this time, only the polarographic oxygen-sensor and the
exogenous hypoxia marker pimonidazole (PIMO) can be con-
sidered as ‘standard’. These methods may have limitations in
clinical settings due to the invasive character of the method, the
limited accessibility of the tumours and the possibility of sampling
errors. Therefore, methods for noninvasive detection of hypoxia
are under continued development. These methods include
magnetic resonance imaging techniques (Robinson et al, 1998;
Mason et al, 1999; Landuyt et al, 2001) and the detection of
sensitiser adducts with SPECT and PET (Chapman et al, 1998;
Ballinger, 2001; Hoebers et al, 2002; Van de Wiele et al, 2003).
The most widely used PET radiotracer for imaging tumour
hypoxia is [
18F]Fluoromisonidazole ([
18F]FMISO). The use of
labelled 2-nitroimidazole compounds is based on studies with
[
3H]misonidazole binding in several human tumour types
(Urtasun et al, 1986). Although the [
3H]misonidazole approach
had limited clinical utility, it was the start of the development of
noninvasive hypoxia markers based on 2-nitroimidazoles. The
selective binding of [
18F]FMISO to hypoxic cells has been
demonstrated in vitro as well as preclinically in vivo (Rasey et al,
1989; Koh et al, 1992).
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sThe present study reports on advances towards the in vivo
validation of [
18F]FMISO for the evaluation of tumour hypoxia.
This was carried out by comparing [
18F]FMISO-PET measure-
ments with immunohistochemical analysis using PIMO, another
nitroimidazole which is established as an exogenous intracellular
hypoxia marker. To obtain potential complementary information,
comparison was made with an endogenous transmembranous
hypoxia marker carbonic anhydrase IX (CA IX). To our knowl-
edge, it is the first time that [
18F]FMISO uptake measured with
PET was compared with PIMO, and additionally with CA IX
staining, to evaluate hypoxic volumes in tumours.
MATERIALS AND METHODS
Animals and tumour model
Male adult WAG/Rij rats with an average body weight of 300g were
used. Each rat was subcutaneously implanted under anaesthetics
with syngeneic rhabdomyosarcomas (1-mm
3 R1 tumours) in the
lateral thorax or in the abdominal flank. After 12 days, when
tumours reached the predetermined range of volumes, PET
measurements were carried out during a 2-week follow-up. Each
day, tumours were measured, using a Vernier calliper, in three
orthogonal tumour diameters A, B and C, each corrected for the
thickness of the skin. Volumes were calculated using the formula
A B C p/6, since the tumours grew elliptically. All animal
experiments were conducted in accordance with local institutional
guidelines, approved by the Animal Ethics Committee of the
University ‘KU Leuven’ and procedures were according to the
guidelines defined by the UKCCCR (Workman et al, 1998).
Radiolabelled tracer
1-(2-nitro-imidazolyl)-3-[
18F]-fluoro-2-propanol ([
18F]Fluoromi-
sonidazole; [
18F]FMISO) was produced by the nucleophilic
fluorination of 1-(20-nitro-10-imidazolyl)-2-O-tetrahydropyranyl-
3-O-toluenesulphonylpropandiole followed by acidic hydrolysis of
the protecting group, as described by Lim and Berridge (1993).
Experimental set-up
When PET measurements were started, each rat received
[
18F]FMISO every 2 days. The rats were anaesthetised with
0.1ml100g
 1 body weight sodium pentobarbital (Nembutal;
Sanofi, Belgium), injected intraperitoneally. The radiolabelled
tracer was administrated via an intravenous line (Venoflux
0.4mm G.27; Vygon, France) inserted into a lateral tail vein,
flushed with heparin saline solution. During PET examinations,
anaesthesia was maintained using individual rat-adapted intraper-
itoneal injections (10–30% of the initial dose) of the anaesthetic, as
needed.
PET imaging
Each PET examination was performed on an ECAT HR
þ scanner
(Siemens, Knoxville, TN, USA), with an axial field of view of 15cm
and a spatial resolution of 6mm full-width at half-maximum
(FWHM) at the centre of the field of view. Before positioning, four
rats were placed in a custom-built, polystyrene foam that was
placed in the opening of the camera. Whole-body scanning was
performed with 63 axial slices, each of 2.425mm, in a single 15-cm
field of view, yielding radioactivity concentration measurements in
voxels of 1.6875 1.6875 2.425mm
3. The [
18F]FMISO-PET ac-
quisition started with a 15-min transmission scan using external
rods of
68Ge to correct for attenuation. An average of 17.02MBq
(13.38–21.24MBq) [
18F]FMISO was injected into a lateral tail vein.
Simultaneously, a dynamic emission scanning was started for
60min, according to the following protocol: 8 15s, 4 30s,
2 1min, 2 2min, 10 5min. At 2h postinjection (p.i.), a
second dynamic emission scanning was carried out for 20min
(4 5min). Preceding this second scanning, a 15-min transmis-
sion scan was performed after repositioning the rats. All images
were reconstructed iteratively in a 128 128 63 matrix using
attenuation factors measured by the transmission scans. The
images were corrected for scatter and randoms, frame duration
and decay to the start of each emission scan. The radioactivity
measured in selected tissues, determined on the images, was
subsequently corrected for decay towards the time of injection.
PET image analysis
To obtain mean activity data of the blood pool, a region of interest
(2D-ROI), representing a volume of 0.425cm
3, was drawn at the
efflux area of the heart on the 2h p.i. [
18F]FMISO images. The
efflux area of the heart was defined with the aid of the early
[
18F]FMISO perfusion images (summation of 1–4min of the first
dynamic acquisition). Normal tissue evaluation was carried out
using 2D-ROI analysis of the lung, muscle (cf Koh et al, 1992) and
a body area 15mm above the heart (cf Bentzen et al, 2000), and
normal tissue to heart mean activity ratios were calculated. To
assess the volume of [
18F]FMISO uptake in tumours, different
absolute thresholds were used, ranging from 1.2 to 3.0. A 3D-ROI
was defined on the 2h p.i. [
18F]FMISO images to select all the
voxels with activity higher than a selected absolute threshold.
Pimonidazole administration
During the 2-week follow-up, a rat was killed daily to enable
immunohistochemical analyses of tumour volumes ranging
between 0.9 and 7.3cm
3. A total of 11 tumours were selected to
cover the full volume range. Each rat received 0.1ml100g
 1 body
weight of pimonidazole hydrochloride (Hypoxyprobe-1; NPI,
Belmont, MA, USA) intraperitoneal prior to the start of the second
dynamic emission scanning. At 1h p.i. of PIMO (i.e. 40min after
the end of scanning), the rat was killed and the tumours were
rapidly excised for immunohistochemical processing.
Immunohistochemistry
Excised tumours were fixed in neutral-buffered formalin and axial
2mm sections were made (n¼3–6, depending on tumour size),
according to the PET plane separation thickness, prior to
embedding in paraffin. Slices (5mm) from each axial section were
deparaffinised with toluene and rehydrated by treatment with a
series of alcohol and water mixtures and finally with water. To
quench endogenous peroxidase, the tissue sections were exposed
for 30min to 0.3% hydrogen peroxide absolute methanol.
Microwave heating (4min 500W, 20min defrost and 15min RT)
was used in the presence of Tris EDTA buffer (0.01 M pH¼9.0) to
achieve antigen retrieval prior to the application of the primary
monoclonal antibody. Phosphate-buffered saline (PBS 0.1 M
pH¼7.3) plus Tween 20 (polyoxyethylene sorbitan monolaurate)
were used to wash slides between two steps. The sections were
incubated in anti-PIMO MAb (1:100 dilution in PBS) for 30min.
Secondary incubation with peroxidase-labelled anti-mouse Envi-
sion (DAKO Corporation, Carpinteria, CA, USA) was applied also
for 30min. Bound peroxidase was developed using 0.033%
hydrogen peroxide in 10% diaminobenzidine (DAB; DAKO
Corporation, Carpinteria, CA, USA) for 7min. After washing in
distilled water, the sections were counterstained with haematoxylin
for 1min, dehydrated and mounted.
Sections contiguous to those stained for PIMO binding were
immunostained for the presence of CA IX in the same manner that
was used for PIMO adducts. M75 MAb (Bayer, USA; Pastorekova
et al, 1992) was used as primary antibody (1:25 dilution in PBS).
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a negative control for both antibodies.
Immunostained sections (n¼50 both for PIMO and for CA IX)
of the selected tumours (n¼11) were viewed by means of a Zeiss
Axioskop 40 FL microscope (Carl Zeiss, Inc., Thornwood, NY,
USA). Each section was evaluated independently by two investi-
gators (LD and WL) and scored by means of moving a ‘10 10’
grid-incorporated ocular, superimposed on the image, at a total
magnification of  200. Five hit-points in every grid, lying on the
intersection of the grid lines, were evaluated for positive PIMO and
CA IX staining in contiguous sections (Weibel, 1981). For each
tumour, depending on the size, 350–1260 hit-points were
evaluated for PIMO and CA IX separately, and the respective
fraction staining positive was calculated. Care was taken that the
hit-points covered the entire tumour area.
Autoradiography
In two tumour-bearing rats, an autoradiography experiment was
carried out. The experimental set-up was the same as described
above, but without carrying out the actual PET imaging. An
average of 84.75MBq (78.13–91.37MBq) [
18F]FMISO was injected
intravenous via the tail vein. At 150min p.i., the rats were killed,
the tumours quickly removed and immediately frozen in 2-
methylbutane (cooled to  251C with liquid nitrogen). The
tumours were cut with a Leica CM 3050 cryotome (Germany) in
14mm-thick slices at each sectional plane of 2mm and mounted on
microscope slides. The slices were immediately air dried at 501C
and exposed overnight to a high-performance storage phosphor
screen (Packard, Meriden, USA), which was scanned in a Phosphor
Imager Scanner (Packard Cyclone TM, Meriden, USA). The
resolution of the images expressed in pixel size was 42 42mm
(600d.p.i.).
Statistics
All statistical analysis and graphs are performed with Statistica
(data analysis software system), version 6.0. (Statsoft, Inc., 2001,
Tulsa, OK, USA). Correlation among the variables was analysed
using the ‘Spearman Rank Order Correlation’ and additionally the
relationships were evaluated by linear regression. A ‘Student’s
t-test’ was used to determine the statistical significance of
differences between two independent groups of variables. For all
tests, a P o 0.05 was considered significant.
RESULTS
Immunohistochemical analysis of tumours: PIMO, and CA
IX, positive fraction
Independent of the tumour size (range: 0.9–7.3cm
3), PIMO-
positive staining areas were seen in all tumour sections and they
were heterogeneously distributed along the sections, as shown in
Figure 1. Localisation of the MAb stain was always at a distance
(several cell layers) from a blood vessel, most often near an area of
necrosis, in peripheral as well as central parts of the sections.
Similar heterogeneous staining areas were found in CA IX-stained
sections.
After microscopic grid-based analysis of the immunostained
sections, the staining-positive fraction was calculated for each
tumour (see Table 1). To check the reproducibility, the sections
were evaluated twice by LD. No significant intraobserver difference
(PIMO: P¼0.4469; CA IX: P¼0.7425) was seen with an interval
between scoring of 1 month. Therefore, the mean of the positive
fractions was used in further analyses. Random selected sections
were evaluated by a second observer (WL) independently. No
significant difference (PIMO: P¼0.6950; CA IX: P¼0.1612) was
seen. The mean hypoxic fraction, assessed with PIMO and CA IX
staining, was 18.673.4% and 18.275.6%, respectively. The
relationship between PIMO-positive fraction and CA IX-positive
fraction did not reach statistical significance (r¼0.5182 and
P¼0.1025).
To allow comparison with the [
18F]FMISO volume measured
with PET, the PIMO-positive and CA IX-positive volume (cm
3) was
calculated by multiplying the MAb staining-positive fraction with
the corresponding tumour volume (see Table 1).
[
18F]FMISO analysis of normal tissues and tumours
The distribution of [
18F]FMISO in the rat was determined on the
2h p.i. images. Although a high [
18F]FMISO uptake was found in
the gastrointestinal region, tumours could be clearly localised.
V
V
P
P
N
N
A B
Figure 1 Pimonidazole staining photographs (made with Carl Zeiss KS100 Software). (A) Peripheral view. (B) Central view. Both slices are shown on a
magnification  25. Scale bar is 40mm. Abbreviations: N¼necrosis, V¼viable, well-oxygenated tumour tissue, P¼PIMO-positive staining and the arrow
indicates a blood vessel.
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18F]FMISO uptake in normal tissue was evaluated using
2D-ROIs on the lung, muscle and a body area 15mm above the
heart. Figure 2 shows a composite histogram of the calculated
tissue to heart ratios. A clear separation of the mean activity ratios
is observed at 1.1 between normal and tumour tissue.
To define the volume of [
18F]FMISO uptake in the tumours,
different thresholds ranging between 1.2 and 3.0 were used. The
use of the lowest threshold (1.2) resulted in [
18F]FMISO volumes
that were larger than the calliper-defined tumour volume. The
correlation for the various thresholds above 1.4 between the
[
18F]FMISO volume and the PIMO-positive and CA IX-positive
volumes is shown in Figure 3. The P-value for each correlation is
also given.
Autoradiography data
[
18F]FMISO was heterogeneously distributed within tumours.
More heterogeneity was, however, seen in the central part of the
tumour, showing regions with high uptake and regions with little
uptake. In the central part of the tumour, a factor 7 difference was
observed between the highest and lowest intensity of [
18F]FMISO
uptake. The lowest intensity of the central part was equal to the
mean intensity of the peripheral part of the tumour. This
phenomenon was seen in both large tumours (see Figure 4A)
and small tumours (see Figure 4B). For larger tumours, larger
areas without [
18F]FMISO labelling were seen.
DISCUSSION
The knowledge that hypoxia influences the outcome of many
cancer treatment modalities emphasises the necessity to measure
these hypoxic cell populations in individual tumours. Comparative
studies allow validation of novel methodologies by comparison
with established ‘so-called standard’ techniques. Only two
comparative studies between noninvasive [
18F]FMISO-PET and
‘standard’ hypoxia measurements have been published to date.
Table 1 Tumour volumes, PIMO-positive and CA IX-positive fractions, with their mean value and standard deviation and PIMO-positive and CA IX-
positive volumes for 11 rhabdomyosarcoma (R1) tumours transplanted in WAG/Rij rats
n¼11
Tumour volume
(cm
3)
PIMO-positive
fraction
CA IX-positive
fraction
PIMO-positive
volume (cm
3)
CA IX-positive
volume (cm
3)
0.89 0.197 0.195 0.175 0.174
0.90 0.185 0.165 0.167 0.149
0.93 0.115 0.112 0.106 0.104
1.00 0.174 0.133 0.174 0.133
2.57 0.215 0.260 0.553 0.668
2.76 0.204 0.149 0.563 0.410
2.88 0.196 0.175 0.563 0.504
3.33 0.185 0.236 0.614 0.786
4.79 0.250 0.225 1.198 1.078
4.95 0.157 0.099 0.775 0.490
7.31 0.172 0.252 1.257 1.838
Mean 0.1861 0.1818
Standard deviation 0.0343 0.0562
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Figure 2 [
18F]FMISO-PET mean tissue to heart activity ratios of the lung (n¼12) , muscle (n¼24; that is, front leg muscle n¼12 and hind leg muscle
n¼12) & and a body area 15mm above the heart (n¼12) ’ on 12 randomly chosen 2h p.i. images. Similarly, tumours (n¼48) were analysed on 2h
p.i. images. For all the tissues, cumulative histogram analysis was carried out.
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sBentzen et al (2002) found no correlation between [
18F]FMISO-
PET and pO2 electrode measurements in C3H mammary
carcinomas. Piert et al (1999, 2000) showed a correlation between
[
18F]FMISO-PET data and pO2 electrode measurements in a study
of hypoxia in pig liver tissue. Until today, however, the potential of
this PET technique still needs confirmation by appropriate
procedures, such as comparative evaluation with nitroimidazole-
related assays.
In the present study, the noninvasive [
18F]FMISO-PET method
for the evaluation of hypoxia in experimental rat tumours was
further validated with immunohistochemical staining techniques
using the nitroimidazole PIMO, a ‘standard’ exogenous hypoxia
marker, and morphometry. In addition, also CA IX, an endogen-
ous indicator of hypoxia, was used. Microscopy-based point
counting, a method used in morphometric tissue analysis (Weibel,
1981) and also in our study, is next to computerised image analysis
shown to be an adequate method for quantification of hypoxia in
tumours (Varia et al, 1998).
[
18F]FMISO volumes are the direct result of the PET analysis. To
compare these data with the immunohistochemical measurements,
the staining-positive fractions of PIMO and CA IX were multiplied
with the corresponding tumour volumes to obtain the respective
hypoxic volumes. The decision to use hypoxic volumes rather than
hypoxic fractions is also supported by Rajendran et al (2003), who
discussed the fact that the use of hypoxic fractions is a variable
with considerable uncertainty.
In a range between 1.4 and 2.2, the hypoxic volumes obtained
with [
18F]FMISO-PET correlated to the same high statistical
significance with the PIMO-derived hypoxic volumes. A similar
observation was made with the CA IX-derived hypoxic volumes.
Although only a slight decrease in correlation was calculated, a
dropout of data was present at a threshold above 2.2. The choice to
use the 2h p.i. [
18F]FMISO-PET images was made for the
evaluation of the tracer uptake, because this time point has been
shown to be optimal for the examination of [
18F]FMISO uptake in
tumours both in animal models (Kubota et al, 1999; Tochon-
Danguy et al, 2002) and in humans (Koh et al, 1992; Valk et al,
1992). Selection of normal tissue (lung, muscle and a body area
15mm above the heart) for image analysis at 2h p.i. using 2D
ROIs, was performed in agreement with the literature (Koh et al,
1992; Bentzen et al, 2000). Mean activity ratios were calculated and
99% of the analysed ratios were below 1.1. Tumour analysis
indicated that using thresholds below 1.4 did not seem useful,
because results indicated that the [
18F]FMISO volume was larger
than the calliper-defined tumour volume. This can be explained by
the spatial resolution of the PET system, where the relatively large
voxels, which encompass partial hypoxic regions, are considered
as completely hypoxic. Based on these normal and tumour tissue
observations, a threshold of 1.4 was defined as cutoff value and as
indicator of significant hypoxia. This cutoff value is in agreement
with the results of Koh et al (1992).
We are aware that within the rhabdomyosarcoma tumour type
the hypoxic volumes tend to increase with tumour size. This is
however tumour type dependent and we realise therefore that the
same comparisons need to be carried out in other tumour models,
at best where this relationship does not hold. A positive relation-
ship between the hypoxic volumes assessed with [
18F]FMISO-PET
and PIMO staining was to some extent anticipated. Indeed, both
are 2-nitroimidazoles, which have the same nitroreduction
mechanism, and are thus expected to bind to intracellular
macromolecules in cells exposed to equal microenvironmental
hypoxia conditions (Raleigh and Koch, 1990; Casciari et al, 1995).
The comparison between [
18F]FMISO-PET and CA IX staining was
also investigated, resulting in a similar strong correlation and
significance. However, a factor 4 difference was found, which may
be explained by the inferior resolution and the large voxel size of
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Figure 3 (A)[
18F]FMISO volume defined on 2h p.i. images, using a threshold 1.4 plotted against PIMO-positive volume (n¼11 tumours). (B) r- and P-
values for a range of thresholds between 1.4 and 3.0 for the same comparison. (C)[
18F]FMISO volume defined on 2h p.i. images, using a threshold 1.4
plotted against CA IX-positive volume (n¼11 tumours). (D) r- and P-values for a range of thresholds between 1.4 and 3.0 for the same comparison.
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extent of a positive correlation between immunohistochemical
staining results for these markers is the subject of a controversial
discussion. Although Olive et al (2001) found a very strong
correlation (r¼0.86, n¼14) in human cervical cancer, Airley et al
(2003) did not find a significant correlation (r¼0.27; P¼0.083,
n¼42). In head and neck cancer, Kaanders et al (2002) found a
weak, but significant correlation (r¼0.36; P¼0.02, n¼42). Lyng
et al (1997), Raleigh et al (1999) and Olive et al (2000) showed for a
number of animal and human tumours that PIMO labelling can
give a reliable estimate of radiobiologically relevant hypoxia. The
variations in correlation between PIMO- and CA IX-stained
hypoxic fractions may be explained by a difference in specificity
of CA IX when compared with PIMO (Kaanders et al, 2002). A
difference in location and area of positive staining (Wykoff et al,
2000; Olive et al, 2001 and also the present study) supports this
explanation. von Hippel-Lindau mutations, which result in an
upregulation of HIF-1a (Cockman et al, 2000) and downstream
components like CA IX (Ashida et al, 2002), and the relationship
between CA IX expression and acidic pH found in tumours
(Stubbs et al, 2000) could potentially contribute to the published
differences.
Autoradiography was performed to determine the [
18F]FMISO
distribution in whole tumours. Different studies have shown
heterogeneity in, for example, larger C3H tumours growing
subcutaneously in CDF1 mice and a more uniform radioactivity
distribution in smaller C3H tumours (Bentzen et al, 2002;
Gro ¨nroos et al, 2004). Tochon-Danguy et al (2002) observed only
homogeneous distribution of [
18F]FMISO throughout C6 glioma
tumours in the left brain of Wistar rats. In the present study, a
heterogeneous distribution of [
18F]FMISO was found both in small
and large rhabdomyosarcoma tumours. More heterogeneity was
observed in central parts of the tumour compared to peripheral
parts. For larger tumours, larger areas with no [
18F]FMISO
labelling were seen, which parallels the fact that larger parts of
these tumours are necrotic. Although no direct comparison was
made on the same sections with the autoradiography data,
immunohistochemical staining with PIMO confirms these results.
A heterogeneous stain was seen in all tumours, both in peripheral
and central parts of the tumour. A similar heterogeneous staining
distribution of hypoxic areas was found in CA IX-stained sections.
These autoradiography and immunohistochemical staining results
support the concept that the microenvironment of solid tumours is
characterised by heterogeneity in oxygenation.
CONCLUSION
The strong and significant relationship between [
18F]FMISO-PET
and PIMO immunohistochemical staining, within a range of
thresholds (1.4–2.2), indicates the value of [
18F]FMISO-PET to
measure hypoxic volumes in whole tumours. Although a positive
correlation between PIMO and CA IX is not a general finding, the
equally significant and strong correlation between [
18F]FMISO-
PET and CA IX immunohistochemical staining strengthens the
application of the noninvasive PET method to evaluate hypoxia.
Given the complex nature of hypoxia development and its impact
on tumour progression and treatment response, it remains highly
important to make additional comparative studies and to relate
[
18F]FMISO measurements with outcome.
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